Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 11Observational 4

Sponsor

Cancer Type

Breast 7Gastrointestinal 6Genitourinary 5Plasma cell 4Thoracic 2Other hematologic neoplasm 2Lymphoid 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Myeloid 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 3

Interventions

Bortezomib 20Blood Specimen Collection 9Surveys and Questionnaires 8Lenalidomide 8Dexamethasone 8pomalidomide 6daratumumab 6Flow Cytometry 6Immunoenzyme Techniques 5Biopsy 5plerixafor 4idecabtagene vicleucel 4carfilzomib 4Standard of Care 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4Specimen Handling 3Psychiatric Rehabilitation 3Patient Reported Outcome Measures 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3Drug Therapy 3Data Collection 3Cytogenetic Analysis 3Chromatin Immunoprecipitation Sequencing 3talquetamab 2selinexor 2belantamab mafodotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Standard of Care × Plasma cell × Clear all
NCT06504524 2025-06-27

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Pfizer

Completed
633 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06592222 2025-05-20

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Pfizer

Completed
4 enrolled
Plasma cell

Multiple Myeloma

NCT05932290 2024-10-29

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
514 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05565391 2024-05-21

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
508 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡